Journal
LEUKEMIA & LYMPHOMA
Volume 56, Issue 7, Pages 2105-2113Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2014.981175
Keywords
Prognosis; transformation; MSI2; leukemia; stem cell
Categories
Funding
- Berliner Krebsgesellschaft e.V. [KAFF201401]
- Novartis
- Wilhelm-Sander Stiftung [2011.018.1]
- Deutsche Jose Carreras Leukamie-Stiftung Fund [DJCLS 10/23]
- Leukaemia Lymphoma NI
- Leukaemia & Lymphoma NI [R2536CNR] Funding Source: researchfish
Ask authors/readers for more resources
A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p < 0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p < 0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABLI mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available